StockNews.com started coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP – Free Report) in a research note published on Thursday morning. The brokerage issued a sell rating on the stock.
Separately, Alliance Global Partners raised their price target on Tonix Pharmaceuticals from $6.00 to $11.00 and gave the company a buy rating in a report on Monday, July 22nd.
View Our Latest Report on TNXP
Tonix Pharmaceuticals Trading Up 6.9 %
Tonix Pharmaceuticals (NASDAQ:TNXP – Get Free Report) last posted its quarterly earnings data on Friday, August 16th. The company reported ($19.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($9.91) by ($9.37). The firm had revenue of $2.21 million for the quarter, compared to analyst estimates of $3.50 million. Tonix Pharmaceuticals had a negative return on equity of 158.27% and a negative net margin of 1,196.11%. As a group, equities analysts expect that Tonix Pharmaceuticals will post -18 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Tonix Pharmaceuticals
A hedge fund recently raised its stake in Tonix Pharmaceuticals stock. Armistice Capital LLC increased its position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP – Free Report) by 160.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,770,000 shares of the company’s stock after acquiring an additional 2,320,000 shares during the quarter. Armistice Capital LLC owned about 14.09% of Tonix Pharmaceuticals worth $1,519,000 as of its most recent SEC filing. 82.26% of the stock is owned by institutional investors.
Tonix Pharmaceuticals Company Profile
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
Featured Stories
- Five stocks we like better than Tonix Pharmaceuticals
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Simon Property REIT: A Safe Bet for Growth and Steady Dividends
- How to Use Stock Screeners to Find Stocks
- CarMax’s Impressive Rally: What Investors Should Watch Next
- What is a Stock Market Index and How Do You Use Them?
- MarketBeat Week in Review – 9/23 – 9/27
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.